


# ADVANCES IN BIOMEDICAL ENGINEERING



EDITOR  
PASCAL VERDONCK

R318  
A244

# ADVANCES IN BIOMEDICAL ENGINEERING

Editor

PASCAL VERDONCK



E2010000875

Amsterdam • Boston • Heidelberg • London • New York • Oxford  
Paris • San Diego • San Francisco • Singapore • Sydney • Tokyo

Elsevier

Radarweg 29, PO Box 211, 1000 AE Amsterdam, The Netherlands  
Linacre House, Jordan Hill, Oxford OX2 8DP, UK

First edition 2009

Copyright © 2009 Elsevier B.V. All rights reserved

No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher

Permissions may be sought directly from Elsevier's Science & Technology Rights Department in Oxford, UK: phone (+44) (0) 1865 843830; fax (+44) (0) 1865 853333; email: [permissions@elsevier.com](mailto:permissions@elsevier.com). Alternatively you can submit your request online by visiting the Elsevier web site at <http://elsevier.com/locate/permissions>, and selecting *Obtaining permission to use Elsevier material*

#### Notice

No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made

#### British Library Cataloguing in Publication Data

A catalogue record for this book is available from the British Library

#### Library of Congress Cataloging-in-Publication Data

A catalog record for this book is available from the Library of Congress

ISBN: 978-0-444-53075-2

For information on all Elsevier publications  
visit our web site at [books.elsevier.com](http://books.elsevier.com)

Printed and bound in Hungary

08 09 10 10 9 8 7 6 5 4 3 2 1

Working together to grow  
libraries in developing countries

[www.elsevier.com](http://www.elsevier.com) | [www.bookaid.org](http://www.bookaid.org) | [www.sabre.org](http://www.sabre.org)

ELSEVIER

BOOK AID  
International

Sabre Foundation



# **ADVANCES IN BIOMEDICAL ENGINEERING**

## PREFACE

The aim of this book is to bridge the interdisciplinary gap in biomedical engineering education. No single medical device has ever been developed without an extensive interdisciplinary collaboration but, nevertheless, a wide gap still exists between different themes like biomaterials, biomechanics, extracorporeal circulation research, nanotechnology, and safety and regulations.

We have to evitate that, due to the growing complexity, we only gather with and communicate in our own expert groups with their specific research topics. Therefore it is, in my opinion, extremely important that a high quality book is available to cover these interdisciplinary islands by bringing representative research groups together. The aim of this book is a top review of current research advances in biomedical engineering but on an educational level, so it is also useful for teaching master's students, Ph.D. students, and professionals. Each chapter is complementary to reviews in specific scientific journals. The topics range from visualization technology and biosignal and imaging analysis over biomechanics and artificial organs to nanotechnology and biophotonics and cardiovascular medical devices. I thank all authors for their support and I sincerely hope this book will contribute to better engineering for health.

Prof. Pascal Verdonck  
December 2007

# LIST OF CONTRIBUTORS

## **C. Blum**

Biophysical Engineering Group, Institute for Biomedical Technology and MESA<sup>+</sup>  
Institute for Nanotechnology, University of Twente, PO Box 217, 7500AE  
Enschede, The Netherlands

## **I. Buvat**

INSERM U678 UPMC, CHU Pitié-Salpêtrière, F-75634 Paris, France

## **P. Comon**

Laboratoire I3S, UNSA-CNRS, Les Algorithmes, Euclide-B, BP 121, 2000  
Route, des Lucioles, 06903 Sophia Antipolis Cedex, France

## **M. De Beule**

Biophysical Engineering Group, Institute for Biomedical Technology and MESA<sup>+</sup>  
Institute for Nanotechnology, University of Twente, PO Box 217, 7500AE  
Enschede, The Netherlands

## **A. Jain**

Biophysical Engineering Group, Institute for Biomedical Technology and MESA<sup>+</sup>  
Institute for Nanotechnology, University of Twente, PO Box 217, 7500AE  
Enschede, The Netherlands; Department of Biotechnology, Indian Institute of  
Technology Kharagpur, Kharagpur, India

## **C.R. Johnson**

Scientific Computing and Imaging Institute, University of Utah, Salt Lake City,  
UT 84112, USA

## **O. Meste**

Laboratoire I3S, UNSA-CNRS, Les Algorithmes, Euclide-B, BP 121, 2000  
Route, des Lucioles, 06903 Sophia Antipolis Cedex, France

## **Z. Nawrat**

Foundation for Cardiac Surgery Development & Medical University of Silesia,  
Poland

## **R. Phlypo**

Biophysical Engineering Group, Institute for Biomedical Technology and MESA<sup>+</sup>  
Institute for Nanotechnology, University of Twente, PO Box 217, 7500AE  
Enschede, The Netherlands

## **S. Staelens**

Biophysical Engineering Group, Institute for Biomedical Technology and MESA<sup>+</sup>  
Institute for Nanotechnology, University of Twente, PO Box 217, 7500AE  
Enschede, The Netherlands

**V. Subramaniam**

Biophysical Engineering Group, Institute for Biomedical Technology and MESA<sup>+</sup>  
Institute for Nanotechnology, University of Twente, PO Box 217, 7500AE  
Enschede, The Netherlands

**X. Tricoche**

Scientific Computing and Imaging Institute, University of Utah, Salt Lake City,  
UT 84112, USA

**V. Zarzoso**

Laboratoire I3S, UNSA-CNRS, Les Algorithmes, Euclide-B, BP 121, 2000  
Route, des Lucioles, 06903 Sophia Antipolis Cedex, France

# CONTENTS

<i>Preface</i>	<i>ix</i>
<i>List of Contributors</i>	<i>xi</i>

<b>1</b>	<b>Review of Research in Cardiovascular Devices</b>	<b>1</b>
	Zbigniew Nawrat	
1	Introduction	2
2	The Heart Diseases	8
3	The Cardiovascular Devices in Open-Heart Surgery	8
3.1	Blood Pumps	9
3.2	Valve Prostheses	23
3.3	Heart Pacemaker	34
4	The Minimally Invasive Cardiology Tools	34
5	The Technology for Atrial Fibrillation	38
6	Minimally Invasive Surgery	39
6.1	The Classical Thoracoscopic Tools	40
6.2	The Surgical Robots	43
6.3	Blood Pumps – MIS Application Study	49
7	The Minimally Invasive Valve Implantation	53
8	Support Technology for Surgery Planning	53
9	Conclusions	57
<b>2</b>	<b>Biomechanical Modeling of Stents: Survey 1997–2007</b>	<b>61</b>
	Matthieu De Beule	
1	Introduction	62
2	Finite Element Modeling of Stents	63
2.1	Finite element basics	63
2.2	Geometrical design and approximation	64
2.3	Material properties	65
2.4	Loading and boundary conditions	66
2.5	Finite element stent design	66
2.6	Effective use of FEA	68
3	Survey of the State of the Art in Stent Modeling: 1997–2007	68
3.1	Neglect of the balloon	69
3.2	Cylindrical balloon	74
3.3	Folded balloon	78
3.4	Summary	81
4	Alternative methods for biomechanical modeling of stents	84
4.1	FEM – Prolapse, flexibility and strut micromechanics	84
4.2	FEM – Self-expandable stents	85
4.3	CFD–drug elution and immersed FEM	87



5	Future Prospects	88
6	Conclusion	88
<b>3</b>	<b>Signal Extraction in Multisensor Biomedical Recordings</b>	<b>95</b>
	Vicente Zarzoso, Ronald Phlypo, Olivier Meste, and Pierre Comon	
1	Introduction	96
1.1	Aim and scope of the chapter	96
1.2	Mathematical notations	97
2	Genesis of Biomedical Signals	98
2.1	A biomedical source model	98
2.2	Cardiac signals	101
2.3	Brain signals	105
3	Multi-Reference Optimal Wiener Filtering	109
3.1	Non-invasive fetal ECG extraction	109
3.2	Optimal Wiener filtering	110
3.3	Adaptive noise cancellation	112
3.4	Results	113
4	Spatio-Temporal Cancellation	115
4.1	Atrial activity extraction in atrial fibrillation	115
4.2	Spatio-temporal cancellation of the QRS complex in AF episodes	117
5	Blind Source Separation (BSS)	123
5.1	The isolation of interictal epileptic discharges in the EEG	123
5.2	Modeling and assumptions	125
5.3	Inherent indeterminacies	127
5.4	Statistical independence, higher-order statistics and non-Gaussianity	127
5.5	Independent component analysis	129
5.6	Algorithms	131
5.7	Results	133
5.8	Incorporating prior information into the separation model	136
5.9	Independent subspaces	138
5.10	Softening the stationarity constraint	138
5.11	Revealing more sources than sensor signals	138
6	Summary, Conclusions and Outlook	139
<b>4</b>	<b>Fluorescence Lifetime Spectroscopy and Imaging of Visible Fluorescent Proteins</b>	<b>145</b>
	Ankur Jain, Christian Blum, and Vinod Subramaniam	
1	Introduction	146
2	Introduction to Fluorescence	146
2.1	Interaction of light with matter	146
2.2	The Jabłoński diagram	147
2.3	Fluorescence parameters	151

2.4	Fluorescence lifetime	151
2.5	Measurement of fluorescence lifetime	153
2.6	Fluorescence anisotropy and polarization	155
2.7	Factors affecting fluorescence	157
3	Fluorophores and Fluorescent Proteins	160
3.1	Green fluorescent protein	161
3.2	Red fluorescent protein	165
4	Applications of VFPS	166
4.1	Lifetime spectroscopy and imaging of VFPS	167
5	Concluding Remarks	170
<b>5</b>	<b>Monte Carlo Simulations in Nuclear Medicine Imaging</b>	<b>175</b>
	Steven Staelens and Irène Buvat	
1	Introduction	176
2	Nuclear Medicine Imaging	176
2.1	Single photon imaging	177
2.2	Positron emission tomography	178
2.3	Emission tomography in small animal imaging	179
2.4	Reconstruction	179
3	The MC Method	180
3.1	Random numbers	180
3.2	Sampling methods	181
3.3	Photon transport modeling	182
3.4	Scoring	183
4	Relevance of Accurate MC Simulations in Nuclear Medicine	184
4.1	Studying detector design	184
4.2	Analysing quantification issues	184
4.3	Correction methods for image degradations	185
4.4	Detection tasks using MC simulations	186
4.5	Applications in other domains	186
5	Available MC Simulators	187
6	Gate	188
6.1	Basic features	188
6.2	GATE: Time management	192
6.3	GATE: Digitization	193
7	Efficiency-Accuracy Trade-Off	194
7.1	Accuracy and validation	194
7.2	Calculation time	194
8	Case Studies	195
8.1	Case study I: TOF-PET	195
8.2	Case study II: Assessment of PVE correction	196
8.3	Case study III: MC-based reconstruction	197
9	Future Prospects	200
10	Conclusion	200

<b>6</b>	<b>Biomedical Visualization</b>	<b>209</b>
	Chris R. Johnson and Xavier Tricoche	
1	Introduction	210
2	Scalar Field Visualization	211
2.1	Direct volume rendering	211
2.2	Isosurface extraction	220
2.3	Time-dependent scalar field visualization	222
3	Vector Field Visualization	223
3.1	Vector field methods in scientific visualization	224
3.2	Streamline-based techniques	225
3.3	Stream surfaces	226
3.4	Texture representations	229
3.5	Topology	232
4	Tensor Field Visualization	234
4.1	Anisotropy and tensor invariants	235
4.2	Color coding of major eigenvector orientation	236
4.3	Tensor glyphs	236
4.4	Fiber tractography	239
4.5	Volume rendering	241
4.6	White matter segmentation using tensor invariants	244
5	Multi-field Visualization	245
6	Error and Uncertainty Visualization	250
7	Visualization Software	254
7.1	SCIRun/BioPSE visualization tools	255
7.2	map3d	258
8	Summary and Conclusion	263
	<i>Index</i>	273

# REVIEW OF RESEARCH IN CARDIOVASCULAR DEVICES

Zbigniew Nawrat

## Contents

1. Introduction	2
2. The Heart Diseases	8
3. The Cardiovascular Devices in Open-Heart Surgery	8
3.1. Blood Pumps	9
3.2. Valve Prostheses	23
3.3. Heart Pacemaker	34
4. The Minimally Invasive Cardiology Tools	34
5. The Technology for Atrial Fibrillation	38
6. Minimally Invasive Surgery	39
6.1. The Classical Thoracoscopic Tools	40
6.2. The Surgical Robots	43
6.3. Blood Pumps – MIS Application Study	49
7. The Minimally Invasive Valve Implantation	53
8. Support Technology for Surgery Planning	53
9. Conclusions	57
Acknowledgments	58
References	58

## Abstract

An explosion in multidisciplinary research, combining mechanical, chemical, and electrical engineering with physiology and medicine, during the 1960s created huge advances in modern health care. In cardiovascular therapy, lifesaving implantable defibrillators, ventricular assist devices, catheter-based ablation devices, vascular stent technology, and cell and tissue engineering technologies have been introduced. The latest and leading technology presents robots intended to keep the surgeon in the most comfortable, dexterous, and ergonomic position during the entire procedure. The branch of the medical and rehabilitation robotics includes the manipulators and robots providing surgery, therapy, prosthetics, and rehabilitation. This chapter provides an overview of research in cardiac surgery devices.

**Keywords:** Heart prostheses, valve prostheses, blood pumps, stents, training and expert systems, surgical tools, medical robots, biomaterials



## 1. INTRODUCTION

Remarkable advances in biomedical engineering create new possibilities of help for people with heart diseases. This chapter provides an overview of research in cardiac surgery devices. An explosion in multidisciplinary research, combining mechanical, chemical, and electrical engineering with physiology and medicine, during the 1960s created huge advances in modern health care. This decade opened new possibilities in aerospace traveling and in human body organ replacement. *Homo sapiens* after World War II trauma became not only the hero of mind and progress but also the creator of the culture of freedom. Computed tomographic (CT) scanning was developed at EMI Research Laboratories (Hayes, Middlesex, England) funded in part by the success of EMI's Beatles records. Modern medical imaging techniques such as CT, nuclear magnetic resonance (NMR), and ultrasonic imaging enable the surgeon to have a very precise representation of internal anatomy as preoperative scans. It creates possibilities of realizing new intervention methods, for instance, the very popular bypass surgery. It was a revolution in disease diagnosis and generally in medicine. In cardiovascular therapy, lifesaving implantable defibrillators, ventricular assist devices (VADs), catheter-based ablation devices, vascular stent technology, and cell and tissue engineering technologies have been introduced.

Currently, the number of people on Earth is more than 6 billion: increasingly lesser number of living organisms and about million increasingly more "intelligent" robots accompany them.

Robotics, a technical discipline, deals with the synthesis of certain functions of the human using some mechanisms, sensors, actuators, and computers. Among many types of robotics is the medical and rehabilitation robotics – the latest but rapidly developing branch at present, which includes the manipulators and robots providing surgery, therapy, prosthetics, and rehabilitation. They help fight pareses in humans and can also fulfill the role of a patient's assistant. Rehabilitation manipulators can be steered using ergonomic user interfaces – e.g., the head, the chin, and eye movements. The "nurse" robots for patients and physically challenged persons' service are being developed very quickly. Partially or fully robotic devices help in almost all life actions, such as person moving or consuming meals, simple mechanical devices, science education, and entertainment activities. Help-Mate, an already existing robot-nurse, moving on the hospital corridors and rooms delivers meals, helps find the right way, etc.

On the one hand, robots are created that resemble the human body in appearance (humanoids), able to direct care; on the other hand, robotic devices are constructed – telemanipulators – controlled by the human tools allowing to improve the precision of human tasks. Robots such as ISAC (Highbrow Soft Arm Control) or HelpMate can replace several functions of the nurse, who will give information, help find the way, bring the medicines and the meal. In case of lack of qualified staff, to provide care for hospice patients at home, these robots will be of irreplaceable help.

Robotic surgery was born out of microsurgery and endoscopic experience. Minimally invasive interventions require a multitude of technical devices: cameras, light sources, special tools (offering the mechanical efficiency and tissue coagulation for

preventing bleeding), and insufflations (thanks to advances in computer engineering, electronics, optics, materials, and miniaturization). The mobility of instruments is decreased [from seven, natural for human arm, to four degrees of freedom (DOFs)] due to the invariant point of insertion through the patient's body wall. Across the world, physicians and engineers are working together toward developing increasingly effective instruments to enable surgery using the latest technology. The leading technology presents robots intended to keep the surgeon in the most comfortable, dexterous, and ergonomic position during the entire procedure. The surgery is complex and requires precise control of position and force. The basic advantages of minimally invasive robot-aided surgery are safe, reliable, and repeatable operative results with less patient pain, trauma, and recovery time. Conventional open-heart surgery requires full median sternotomy, which means cracking of sternum, compromising pulmonary function, and considerable loss of blood.

### Milestones in the Evolution of Cardiac Devices

1628	William Harvey, St Bartholomew's Hospital, London, presented his theory of the circulatory system. He described the function of the heart, arteries, and veins. It is considered to be one of the greatest advances in medicine.
1812	Julien-Jean Cesar LeGallois, a French physician, proposed the idea of artificial circulation.
1882	German von Schröder introduced the first bubble oxygenator.
1929	Werner Forssmann, a German surgeon, developed the technique of cardiac catheterization, the first to document right heart catheterization in humans using radiographic techniques (won the Nobel Prize in 1956).
1934	Dr Michael DeBakey invented the DeBakey pump (peristaltic).
1937	Artificial heart designed by the Soviet scientist W.P. Demichow was first successfully applied on the dog for 5.5 h.
1949	IBM developed the Gibbon Model I heart-lung machine, delivered to Jefferson Medical College, Philadelphia, PA, USA. It consisted of DeBakey pumps and film oxygenator.
1952	Paul Zoll developed the first cardiac pacemaker.
1952	Charles Hufnagel sewed an artificial valve into a patient's aorta.
1953	Dr John H. Gibbon, Jr, Jefferson Medical College Hospital, Philadelphia, PA, USA, first successfully applied extracorporeal circulation in an 18-year-old female with an atrial septal defect.
1953	Dr Michael DeBakey, Baylor University, Houston, TX, USA, implanted a seamless, knit Dacron tube for surgical repairs and/or replacement of occluded vessels or vascular aneurysms.
1957	Wild et al. reported the use of ultrasound to visualize the heart noninvasively.
1957	Dr C. Walton Lillehei and Earl Bakken, an electronic engineer, developed the first portable pacemaker. Bakken later formed the Medtronic Corporation.
1957	Drs William Kolff and Tetsuzo Akutsu at the Cleveland Clinic implanted the first artificial heart in a dog. The animal survived for 90 min.

- |           |   |
|-----------|---|
| 1958      | Dr Mason Sones, a cardiologist at the Cleveland Clinic Foundation, developed coronary angiography.  |
| 1960s     | Semm et al. developed laparoscopic instrumentation.   |
| 1960      | Dr Albert Starr, an Oregon surgeon, developed the Starr–Edwards heart valve. One of the most successful heart valves produced until the late 1970s.   |
| 1967      | René Favaloro, an Argentine surgeon in the United States, performed the first coronary bypass operation using the patient’s native saphenous vein as an autograft.  |
| 1967      | Christiaan Barnard performed the first heart transplantation.   |
| 1968      | A. Kantrowitz et al. performed the first clinical trial in a man with intra-aortic balloon pumping.   |
| 1969      | Dr Denton Cooley, Texas Heart Institute, Houston, TX, USA, implanted a total artificial heart (TAH) designed by Domingo Liotta. The device served as a “bridge” to heart transplantation until a donor heart was found, for 64 h. The heart transplant functioned for an additional 32 h until the patient died of pneumonia. |
| 1971      | White – ECMO on newborn babies using veno-venous bypass for up to 9 days.   |
| 1975      | A. Gruentzing developed the first balloon catheter.   |
| 1975      | Dr Willem Kolff, University of Utah, designed a nuclear-powered artificial heart (Westinghouse Corporation).  |
| 1975      | BioMedicus BioPump (Centrifugal) introduced for clinical applications.  |
| 1975      | Computerized axial tomography, the “CAT scanner”, was introduced.   |
| 1977      | Newer generations of mechanical prostheses included the monoleaflet (Medtronic–Hall) and the bileaflet (St Jude Medical).   |
| 1979      | The Jarvik TAH was designed using a flexible four-layer diaphragm and a structural design that fits in the human chest. This design was a larger 100 cc version of today’s CardioWest TAH–t, which is 70 cc.  |
| 1981      | Dr Denton Cooley implanted another pneumatically driven artificial heart designed by Dr Akutsu. This artificial heart was used for 27 h as a “bridge” to cardiac transplantation.   |
| 1982      | Dr William DeVries implanted the Jarvik 7 into Barney Clark, DDS. Dr Clark lived for 112 days.  |
| 1984      | Baby girl Faye’s native heart, Loma Linda Medical Center, was explanted and replaced with a baboon heart. She survived for 3 weeks.   |
| 1984      | First human implant and successful bridge-to-transplant – a Novacor® LVAS.  |
| 1985      | The FDA gave approval for Hershey Medical Center to perform six PennState artificial heart implants as bridges to human heart transplantations. This heart is no longer used with human subjects.   |
| 1985      | At the University of Arizona, Dr Jack Copeland implanted a prototype TAH in a patient who had rejected a recently transplanted heart.   |
| 1986      | The first atherectomy devices that remove material from the vessel wall were introduced.  |
| 1987      | Introduction of the first use of coronary stent (by 1997, more than 1 million angioplasties had been performed worldwide).  |
| 1990      | First LVAS patient discharged home with a Novacor LVAS.   |
| 1990–1992 | The FDA had withdrawn the Investigational Device Exemption (IDE) from Symbion for the clinical study of the Jarvik TAH. Symbion   |

	subsequently donated the TAH technology to University Medical Center (UMC), Tucson, AZ, USA, which reincorporated the company and renamed it CardioWest.
1994	First FDA-approved robot for assisting surgery [automated endoscopic system for optimal positioning (AESOP) produced by Computer Motion (CM; Goleta, CA, USA)].
1994	FDA approved the pneumatically driven HeartMate <sup>®</sup> LVAD (Thoratec Corporation, Burlington, MA, USA) for bridge to transplantation (the first pump with textured blood-contacting surfaces).
1994	HeartMate LVAS has been approved as a bridge to cardiac transplantation.
1996	REMATCH Trial (Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart failure, E. Rose principal investigator) initiated with HeartMate <sup>®</sup> VE (Thoratec Corp.). Results published in 2002 showed mortality reduction of 50% at 1 year as compared to patients receiving optimal medical therapy.
1998	Simultaneous FDA approval of HeartMate VE (Thoratec Corporation, Burlington, MA, USA) and Novacor LVAS (World Heart Corporation, Ontario, Canada), electrically powered, wearable assist systems for bridge to transplantation, utilized in more than 4000 procedures to 2002. Till now, we can estimate 4500 HeartMate XVE, more than 440 IVAD (Implantable Ventricular Assist Device) and more than 1700 Novacor in this kind of blood pump.
1998	First clinical application of next-generation continuous-flow assist devices. DeBakey (MicroMed Inc.) axial-flow pump implanted by R. Hetzer, G. Noon, and M. DeBakey.
1998	Carpentier and Loulmet performed first in the world endoscopic operation of single bypass graft between left internal thoracic artery and left anterior descending (LITA–LAD) and first operation inside the heart – mitral valve plastic and atrial septal defect closure was performed using surgical robot da Vinci (Intuitive Surgical, Sunnyvale, CA, USA).
1998	Mohr and Falk bypass surgery and mitral valve repairs in near endoscopic technique (da Vinci).
1999	First clinical application of a totally implantable circulatory support system. LionHeart LVAS implanted in a 67 year-old male recipient by R. Koerfer and W. Pae.
1999	D. Boyd first totally endoscopic coronary artery bypass graft (E-CABG) using Zeus robot (Computer Motion, CA, USA, currently intuitive surgical, not in the market).
2000	Physicians in Houston US have realised the implantation and have got the first patient in the clinical investigation of the Jarvik 2000 Heart. Jarvik Heart, Inc. and the Texas Heart Institute began developing the Jarvik 2000 Heart in 1988.
2000	THI was granted permission by the Food and Drug Administration to evaluate the Jarvik 2000 Heart as a bridge to transplantation in five patients.
2000	The FDA gave permission to extend the study. Patients have been sustained for more than 400 days with this device. ( <a href="http://www.texasheartinstitute.org/Research/Devices/j2000.cfm">http://www.texasheartinstitute.org/Research/Devices/j2000.cfm</a> ).
2001	The AbioCor was implanted in Robert Tools by cardiac surgeons Laman Gray and Robert Dowling on July 2, 2001, at Jewish Hospital in Louisville, Kentucky. L. Robert Tools aged 59 years with the artificial heart survived 5 months. He died because of the blood clot.



- 2001 Doctors Laman Gray and Robert Dowling in Louisville (KY, USA) implanted the first autonomic artificial heart – AbioCor (Abiomed, Inc., Danvers, MA, USA). The FDA approved the Abiocor for commercial approval under a Humanitarian Device Exemption in September, 2006. ABIOMED is also working on the next generation implantable replacement heart, the AbioCor II. Incorporating technology both from ABIOMED and Penn State, the AbioCor II is smaller and is being designed with a goal of 5-year reliability. The BVS 5000 was the first extracorporeal, or outside the body, ventricular assist device on the market and is still the most widely used bridge to recovery device with systems located in more than 700 institutions throughout the world. Abiomed also offers the Impella 2.5 – a minimally invasive, percutaneous ventricular assist device that allows the heart to rest and recover (<http://www.abiomed.com/products/faqs.cfm>).
- 2001 Drs Laman Gray and Robert Dowling in Louisville (KY, USA) implanted the first autonomic artificial heart – AbioCor (Abiomed Inc., Danvers, MA, USA).
- 2001 The first transatlantic telesurgery – Lindbergh operation – surgeon from New York operated patients in Strasburg using Zeus<sup>®</sup> system.
- 2001 The first full implantable TAH Lion Heart (the Texas Heart Institute in Houston, Abiomed in Danvers, US) was used. The first-ever human implant of the LionHeart<sup>™</sup> left ventricular assist system took place October 26, 1999 at the Hearzzentrum NRW in Bad Oeynhausen, Germany. Eight patients have lived with the device for more than 1 year, and four patients have lived with the device for more than 2 years. The Food and Drug Administration approved the first series of US clinical trials for the Arrow LionHeart<sup>™</sup> heart assist device in February 2001. Penn State Milton S. Hershey Medical Center implanted the device in the first US patient later that month (<http://www.hmc.psu.edu/lionheart/clinical/index.htm>).
- 2001 The first totally implantable TAH LionHeart (the Texas Heart Institute in Houston, TX, USA; Abiomed in Danvers, MA, USA) was used.
- 2002 FDA approved the HeartMate VELVAD for permanent use (Thoratec Corp.).
- 2002 Novacor LVAS became the first implanted heart assist device to support a single patient for longer than 5 years.
- 2002 The first percutaneous aortic valve replacement was performed by Alain Cribier in April of 2002 [xxxx]. To
- 2004 The CardioWest TAH-t becomes the world's first and only FDA-approved temporary total artificial heart (TAH-t). The indication for use is as a bridge to transplant in cardiac transplant patients at risk of imminent death from nonreversible biventricular failure. SynCardia Systems, Inc. (Tucson, AZ, USA) is the manufacturer of the CardioWest<sup>™</sup> TAH-t. It is the only FDA- and CE-approved TAH-t in the world. It is designed for severely ill patients with end-stage biventricular failure. The TAH-t serves as a bridge to human heart transplant for transplant eligible patients who are within days or even hours of death. A New England Journal of Medicine paper published on August 26, 2004 (NEJM 2004; 351: 859–867), states that in the pivotal clinical study of the TAH-t, the 1-year survival rate for patients receiving the CardioWest TAH-t was 70% versus 31% for control patients who did not receive the device. One-year and 5-year survival rates after transplantation among patients who had received a TAH-t as a bridge to human heart transplant were 86% and 64%. The highest bridge to human heart transplant rate of any heart device is 79%